Creative Commons source reading · Brain aging and cognitive reserve
Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium.
Constantinos Constantinides; Laura K M Han; Clara Alloza; Linda Antonella Antonucci; Celso Arango; Rosa Ayesa-Arriola; Nerisa Banaj; Alessandro Bertolino; Stefan Borgwardt; Jason Bruggemann; Juan Bustillo; Oleg Bykhovski; Vince Calhoun; Vaughan Carr; Stanley Catts; Young-Chul Chung; Benedicto Crespo-Facorro; Covadonga M Díaz-Caneja; Gary Donohoe; Stefan Du Plessis; Jesse Edmond; Stefan Ehrlich; Robin Emsley; Lisa T Eyler; Paola Fuentes-Claramonte; Foivos Georgiadis; Melissa Green; Amalia Guerrero-Pedraza; Minji Ha; Tim Hahn; Frans A Henskens; Laurena Holleran; Stephanie Homan; Philipp Homan; Neda Jahanshad; Joost Janssen; Ellen Ji; Stefan Kaiser; Vasily Kaleda; Minah Kim; Woo-Sung Kim; Matthias Kirschner; Peter Kochunov; Yoo Bin Kwak; Jun Soo Kwon; Irina Lebedeva; Jingyu Liu; Patricia Mitchie; Stijn Michielse; David Mothersill; Bryan Mowry; Víctor Ortiz-García de la Foz; Christos Pantelis; Giulio Pergola; Fabrizio Piras; Edith Pomarol-Clotet; Adrian Preda; Yann Quidé; Paul E Rasser; Kelly Rootes-Murdy; Raymond Salvador; Marina Sangiuliano; Salvador Sarró; Ulrich Schall; André Schmidt; Rodney J Scott; Pierluigi Selvaggi; Kang Sim; Antonin Skoch; Gianfranco Spalletta; Filip Spaniel; Sophia I Thomopoulos; David Tomecek; Alexander S Tomyshev; Diana Tordesillas-Gutiérrez; Therese van Amelsvoort; Javier Vázquez-Bourgon; Daniela Vecchio; Aristotle Voineskos; Cynthia S Weickert; Thomas Weickert; Paul M Thompson; Lianne Schmaal; Theo G M van Erp; Jessica Turner; James H Cole; ENIGMA Schizophrenia Consortium; Danai Dima; Esther Walton
Originally published in Molecular psychiatry · 2022-12-09
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]).
Discussion
We assessed brain ageing in 2803 individuals with SZ and 2598 healthy controls using a novel brain age algorithm based on FreeSurfer ROIs. Results indicate that, at a group level, patients with SZ show a greater discrepancy between their brain-predicted age and chronological age compared to healthy individuals (+3.55 years), with a moderate increase in brain-PAD (Cohen’s = 0.48). The greater brain-PAD in the SZ group was not driven by any of the specific clinical characteristics assessed here (age of onset, length of illness, symptom severity, and antipsychotic use and dose). This study has two major strengths.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
